Abiopharma

🔍 Monaco Donald P (Director)

Company: NextTrip, Inc. (NTRP)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 930,927 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-08-25 | Code: J | equity_swap_involved: 0 | shares_owned_after: 3,612.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F4, F1, F5

Footnotes:

• F1: At the election of the Reporting Person, each outstanding share of Series B Preferred Stock (the "Series B Preferred") may be converted to the number of shares of Issuer common stock equal to the quotient obtained by dividing (i) the price per share of Series B Preferred of $1,000, plus accrued and unpaid dividends thereon by (ii) an initial conversion price of $3.88, subject to adjustment under certain limited circumstances, subject to beneficial ownership limitations and rounded down to the nearest whole share.
• F2: The Series B Preferred was acquired from the Issuer in a privately negotiated exchange pursuant to an exchange agreement, in exchange for the cancellation of $3,612,000 aggregate principal amount of non-convertible indebtedness, together with accrued and unpaid interest thereon. The Series B Preferred has a stated value of $1,000 per share.
• F3: The Series B Preferred Stock is immediately convertible at the election of the Reporting Person.
• F4: The Series B Preferred does not expire.
• F5: The shares are beneficially owned by Monaco Investment Partners II, LP ("MI Partners II"). The Reporting Person is the managing general partner of MI Partners II. As such, the Reporting Person is deemed to beneficially own the securities held by the MI Partners II. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by MI Partners II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.